Miniatura

Fitxers

262177.pdf (4.71 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-05-12

Llicència de publicació

cc-by (c) Ortiz-Barahona, V. et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224838

Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12943-023-01785-z

Resum

Background: RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. Methods: Combining data mining and conventional experimental procedures, NSUN7 methylation and expression status was assessed in liver cancer cell lines and primary tumors. Loss-of-function and transfection-mediated recovery experiments coupled with RNA bisulfite sequencing and proteomics determined the activity of NSUN7 in downstream targets and drug sensitivity. Results: In this study, the initial screening for genetic and epigenetic defects of 5-methylcytosine RNA methyltransferases in transformed cell lines, identified that the NOL1/NOP2/Sun domain family member 7 (NSUN7) undergoes promoter CpG island hypermethylation-associated with transcriptional silencing in a cancer-specific manner. NSUN7 epigenetic inactivation was common in liver malignant cells and we coupled bisulfite conversion of cellular RNA with next-generation sequencing (bsRNA-seq) to find the RNA targets of this poorly characterized putative RNA methyltransferase. Using knock-out and restoration-of-function models, we observed that the mRNA of the coiled-coil domain containing 9B (CCDC9B) gene required NSUN7-mediated methylation for transcript stability. Most importantly, proteomic analyses determined that CCDC9B loss impaired protein levels of its partner, the MYC-regulator Influenza Virus NS1A Binding Protein (IVNS1ABP), creating sensitivity to bromodomain inhibitors in liver cancer cells exhibiting NSUN7 epigenetic silencing. The DNA methylation-associated loss of NSUN7 was also observed in primary liver tumors where it was associated with poor overall survival. Interestingly, NSUN7 unmethylated status was enriched in the immune active subclass of liver tumors. Conclusion: The 5-methylcytosine RNA methyltransferase NSUN7 undergoes epigenetic inactivation in liver cancer that prevents correct mRNA methylation. Furthermore, NSUN7 DNA methylation-associated silencing is associated with clinical outcome and distinct therapeutic vulnerability.

Matèries

Epigenètica, Metilació, Càncer de fetge, Citocines

Matèries (anglès)

Epigenetics, Methylation, Liver cancer, Cytokines

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ORTIZ BARAHONA, Vanessa, SOLER, Marta, DAVALOS, Veronica, GARCÍA-PRIETO, Carlos a., JANIN, Maxime, SETIÉN, Fernando, FERNÁNDEZ-REBOLLO, Irene, BECH-SERRA, Joan j., DE LA TORRE, Carolina, GUIL, Sonia, VILLANUEVA GARATACHEA, Alberto, ZHANG, Pei-hong, YANG, Li, GUARNACCI, Marco, SCHUMANN, Ulrike, PREISS, Thomas, BALASEVICIUTE, Ugne, MONTAL, Robert, LLOVET I BAYER, Josep maria, ESTELLER, Manel. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer. _Molecular Cancer_. 2023. Vol. 22. [consulta: 22 de gener de 2026]. ISSN: 1476-4598. [Disponible a: https://hdl.handle.net/2445/224838]

Exportar metadades

JSON - METS

Compartir registre